Kenneth Moch

Kenneth Moch has broad expertise building, financing and leading private and public life science companies from start-up through commercialization, with a focus on the development of novel first-in-class medicines that address unmet needs in chronic and acute life-threatening diseases. As part of current work at Euclidean Venture Studio, he has co-founded and is building four advanced therapeutics companies across muscle repair and regeneration, cancer resistance, neurodevelopmental disorders and anesthesia reversal.

Ken has been responsible for the completion of more than 30 public offerings and private placements, including two market opening IPOs, cumulatively raising over $1 billion in equity and non-dilutive capital for cutting edge research and clinical development programs. He has served as President & CEO and a Board member of five companies: Cognition Therapeutics (Alzheimer’s and other neuro-degenerative diseases); Chimerix (Nasdaq: CMRX; life-threatening viral diseases, acquired by Jazz); BioMedical Enterprises (nitinol orthopedic implants; acquired by J&J); Alteon (Nasdaq: ALTN; cardiovascular diseases and diabetic complications); and Biocyte Corporation, where he pioneered the storage and therapeutic use of cord blood stem cells and launched the first cord blood stem cell storage bank. Ken started his career in biotech drug development as the first businessperson to join The Liposome Company (Nasdaq: LIPO; acquired by Elan), the pioneering company for lipid nanoparticles, one of the most widely used drug delivery/carrier technologies, where he was a co-founder and Vice President. He has also been a Managing Director of Healthcare Investment Banking at ThinkEquity Partners, a founder and Managing General Partner of Catalyst Ventures (seed stage venture capital fund), and a consultant with McKinsey & Company.

Ken served for over 15 years on the Governing Board of BIO, where he held numerous leadership roles, chaired BIO’s Bioethics Committee and co-chaired the Emerging Companies Section Strategy and Policy Committee. He is a past Chairman of BioNJ, New Jersey’s biotechnology trade organization, and a past member of the Executive Committee of the New York Biotechnology Association. Ken has advised numerous biotech and pharmaceutical companies on issues related to preapproval access and is a founding member of the NYU Working Group on Compassionate Use and Pre-Approval Access, and a Faculty Affiliate in Medical Ethics in the Department of Population Health, NYU School of Medicine. Ken has co-authored multiple articles with Arthur Caplan, PhD, on ethical issues surrounding access to experimental medicines. Ken holds an A.B. in biochemistry with a minor in health policy from Princeton University and an MBA from the Stanford University Graduate School of Business.